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Purpose
Tyrosine kinase inhibitors (TKIs) have improved overall
survival of patients with chronic myeloid leukemia (CML).
Moreover, it has been reported that some of the patients
achieve treatment-free remission (TFR) after cessation of
TKIs, even though leukemic stem cells (LSC) of CML are
considered to be resistant to TKIs. Therefore, these find-
ings suggest that remaining LSCs could be eradicated by
immune system after withdrawal of TKIs. In order to clar-
ify the role of anti-LSC immunity in achieving TFR, we
tried to detect cytotoxic T cells against one of the LSC
antigens, KU-MEL9 in CML patients.
Methods
Fresh blood samples were obtained from 16 CML patients
who stopped imatinib after maintained complete molecu-
lar response (CMR) for more than two years at 0,3, and
6 months after cessation of imatinib. Mononuclear cells
were stimulated with LSC antigen, KU-MEL9-derived
nanomer peptide twice in vitro, then stained with anti-
KU-MEL9-specific dextramer and analyzed by flow
cytometry. Immunophenotype of lymphocytes was also
determined by flow cytometry.
Results
We detected KU-MEL9-specific CTLs in 3 of 16 patients
(Table 1). All of these patients remained in CMR at least
12 months after cessation of imatinib. On the other hand,
none of 4 patients who showed molecular relapse pre-
sented with KU-MEL9-specific CTLs. The relapse rate of
patients without KU-MEL9-CTLs was 31.3%, as compared
to 0 % in KU-MEL9-CTL-positive patients. Percentage of
CD4+ CD25+ cells was higher in patients who experienced
loss of CMR.
Conclusion
We found LSC antigen-specific T cells only in patients
who achieved TFR. Although the patient size is small,
these data suggest that anti-LSC CTLs may play a role in
eradicating remaining LSCs after imatinib treatment and
LSC antigen-specific immunotherapy could be useful to
increase TFR rate.
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Table 1
Patients 0m 3m 6m Clinical course
1 - - - Molecular relapse
2 - - - CMR
3 - - + CMR
4 - - - CMR
5 - - - CMR
6 - + - CMR
7 - - - CMR
8 - - - Molecular relapse
9 - - - CMR
10 - - - CMR
11 - - - Molecular relapse
12 - - - Molecular relapse
13 - - - CMR
14 + - - CMR
15 - - - CMR
16 - - - CMR
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